Protocol Ledger

NCT06684847 · Phase III · ACTIVE NOT RECRUITING

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Interventional Phase III clinical trial protocol NCT06684847 sponsored by argenx in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-15 Enrollment: 631 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06684847
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)631 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06684847
Protocol FieldVerified Registry Value
NCT IdentifierNCT06684847
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment631 participants (ACTUAL)
Registered Start Date2025-01-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI